SCILEX HOLDING CO - ACEA THERA TO ACQUIRE APPROXIMATELY 82% OF THE CONTINUING COMPANY AFTER CLOSURE

Written by Emily J. Thompson, Senior Investment Analyst

Source: moomoo

Updated: 5 days ago

0mins

SCLX-2.74%

SCLXW-16.11%

PHOE+26.23%

Should l Buy SCLX?

Source: moomoo

Company Overview: Cilex Holding Co. has a significant stake in the Go-Forward Company, owning approximately 82% of it.
Recent Developments: The ownership stake was confirmed upon the closing of a recent transaction.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy SCLX?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on SCLX

About SCLX

Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

ACEA Therapeutics to be Acquired by Phoenix Asia in $1 Billion Deal

5 days agostocktwits

Deal Details: ACEA Therapeutics will sell 100% of its equity interests in ACEA Pharma to Phoenix Asia for a total transaction value of $1 billion, with Phoenix issuing 100 million new ordinary shares at $10 each, expected to close by Q2 2026, marking a significant shift towards the pharmaceutical industry.
Stock Price Reaction: Shares of Phoenix Asia Holdings (PHOE) surged 169% following the announcement of the deal, reflecting strong market optimism and the potential for further growth in the pharmaceutical sector.
Market Sentiment: On Stocktwits, retail sentiment around SCLX remained in the 'extremely bullish' territory, while PHOE's sentiment jumped from 'bullish' to 'extremely bullish', indicating positive investor reactions and expectations for future potential.
Corporate Restructuring: Upon completion of the deal, Phoenix Asia will be renamed ACEA Pharma, Inc., continuing to trade on Nasdaq, with ACEA Therapeutics projected to own approximately 82% of the new entity, further solidifying its position in the pharmaceutical industry.

Scilex Acquires ACEA Pharma for $1 Billion

5 days agoNewsfilter

Acquisition Overview: Scilex's indirect subsidiary ACEA Therapeutics has entered into an agreement with Phoenix Asia Holdings to sell 100% of ACEA Pharma's equity interests at $10 per share, totaling $1 billion, with completion expected by the end of Q2 2026, marking a strategic expansion in non-opioid pain management.
Equity Structure Change: Upon closing, ACEA Therapeutics anticipates owning approximately 82% of the newly formed ACEA Pharma, enhancing its market control and supporting future product development and commercialization efforts.
Market Listing Plans: The newly established ACEA Pharma is expected to be listed on Nasdaq, which will not only elevate the company's market visibility but also potentially attract more investor interest in its non-opioid pain management products, further driving company growth.
Strategic Implications: This acquisition aligns with Scilex's long-term growth strategy and will enhance its competitive position in the acute and chronic pain treatment market by integrating ACEA Pharma's R&D capabilities to meet the increasing patient demand.